

Research

Open Access

Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States

Harrell W Chesson*, Dayne Collins and Kathryn Koski

Address: Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Email: Harrell W Chesson* - hbc7@cdc.gov; Dayne Collins - DCollins@cdc.gov; Kathryn Koski - KKoski@cdc.gov

* Corresponding author

Published: 23 May 2008

Received: 7 September 2007

Cost Effectiveness and Resource Allocation 2008, **6**:10 doi:10.1186/1478-7547-6-10

Accepted: 23 May 2008

This article is available from: <http://www.resource-allocation.com/content/6/1/10>

© 2008 Chesson et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Sexually transmitted infection (STI) prevention programs can mitigate the health and economic burden of STIs. A tool to estimate the economic benefits of STI programs could prove useful to STI program personnel.

Methods: We developed formulas that can be applied to estimate the direct medical costs and indirect costs (lost productivity) averted by STI programs in the United States. Costs and probabilities for these formulas were based primarily on published studies.

Results: We present a series of formulas that can be used to estimate the economic benefits of STI prevention (in 2006 US dollars), using data routinely collected by STI programs. For example, the averted sequelae costs associated with treating women for chlamydia is given as $(C_w)(0.16)(0.925)(0.70)(\$1,995)$, where C_w is the number of infected women treated for chlamydia, 0.16 is the absolute reduction in the probability of pelvic inflammatory disease (PID) as a result of treatment, 0.925 is an adjustment factor to prevent double-counting of PID averted in women with both chlamydia and gonorrhoea, 0.70 is an adjustment factor to account for the possibility of re-infection, and \$1,995 is the average cost per case of PID, based on published sources.

Conclusion: The formulas developed in this study can be a useful tool for STI program personnel to generate evidence-based estimates of the economic impact of their program and can facilitate the assessment of the cost-effectiveness of their activities.

Background

An estimated 19 million new cases of sexually transmitted infections (STIs) occur each year in the United States, with a price tag of \$12 to \$20 billion (including HIV) in lifetime direct medical costs (in 2006 US dollars) [1-5]. The indirect costs (such as lost productivity) associated with STIs are substantial as well. For example, the lifetime indirect cost per case of HIV in the US is almost \$1 million [6].

STI prevention programs can mitigate the health and economic burden of STIs. A tool to estimate the economic benefits of STI programs could prove useful to STI program personnel. In 1992, the Centers for Disease Control and Prevention (CDC) provided a series of formulas that program personnel could apply to estimate the medical costs offset by the prevention activities of their program [7]. Since that time, the costs of STIs have changed substantially, rendering the 1992 CDC model somewhat

dated. To address the need for more current tools, we developed formulas (loosely based on the 1992 CDC model) that can be applied to estimate the direct medical costs and indirect costs (lost productivity) averted by STI programs in the US.

Methods

We applied a societal perspective and included all relevant costs regardless of who pays these costs [8,9]. We developed formulas that can be applied to estimate the direct medical costs and indirect costs (lost productivity) averted by STI programs. We focused on the benefits of treating people with primary and secondary (P&S) syphilis, gonorrhea, and chlamydia, and the benefits of HIV counseling and testing. These benefits included the sequelae costs averted by treatment of people with STIs, the prevention

of congenital syphilis in infants born to mothers treated for P&S syphilis, the interruption of STI transmission in the population, the reduction in STI-attributable HIV infections (HIV infections that would not have occurred without the facilitative effects of STIs on HIV transmission and acquisition), HIV infections averted by HIV counseling and testing, and the corresponding reductions in lost productivity. Costs and probabilities for these formulas were based on published studies and assumptions, as listed in Table 1 and described below. The first five sections below focus on direct medical costs, and the final section examines indirect costs (lost productivity). Costs were adjusted for inflation to year 2006 US dollars using the medical care component and the all items component (for direct medical costs and indirect costs, respectively)

Table 1: Summary of STI cost estimates (in 2006 US dollars) and selected parameter values applied in the formulas

Parameter	Value applied		Range applied
	Females	Males	
Direct medical costs			
Average cost per case of PID [23–25]	\$1,995	not applicable	± 50%
Average cost per case of epididymitis [26]	not applicable	\$274	± 50%
Average sequelae costs per case of syphilis [5]	\$572*	\$572*	± 50%
Average cost per case of chlamydia [5]	\$315	\$26	± 50%
Average cost per case of gonorrhea [5]	\$343	\$68	± 50%
Average cost per case of syphilis [5]	\$572*	\$572*	± 50%
Average cost per case of HIV [6]	\$198,471	\$198,471	± 50%
Average cost per case of congenital syphilis [1,64,65]	\$6,738	\$6,738	± 50%
Indirect (lost productivity) costs			
Average cost per case of HIV [6]	\$831,614	\$831,614	± 50%
Average cost per untreated case of chlamydia [85]	\$148	\$13	± 50%
Average cost per untreated case of gonorrhea**	\$171	\$34	± 50%
Average cost per untreated case of syphilis**	\$112*	\$112*	± 50%
Average cost per case of chlamydia**	\$47	\$10	± 50%
Average cost per case of gonorrhea**	\$47	\$10	± 50%
Average cost per case of syphilis**	\$112*	\$112*	± 50%
Average cost per case of congenital syphilis**	\$60,421	\$60,421	± 50%
Other parameters			
Absolute reduction in probability of sequelae due to treatment: chlamydia**	0.16	0.03	± 90%
Absolute reduction in probability of sequelae due to treatment: gonorrhea**	0.14	0.03	± 90%
Adjustment to chlamydia costs averted to account for gonorrhea coinfection**	0.925	0.925	± 5%
Adjustment to gonorrhea costs averted to account for chlamydia coinfection**	0.79	0.90	± 5%
Adjustment to account for reinfection: gonorrhea and chlamydia**	0.70	0.70	± 25%
Probability of congenital syphilis given untreated syphilis in mother [63]	0.50	not applicable	± 50%
Number of cases of STI averted in population per STI case treated**	0.50	0.50	± 90%
Probability of a new case of HIV attributable to chlamydia [70]	0.0011	0.0011	± 90%
Probability of a new case of HIV attributable to gonorrhea [70]	0.0007	0.0007	± 90%
Probability of a new case of HIV attributable to syphilis [70]	0.02386	0.02386	± 90%
Adjustment for time frame for STI-attributable HIV infections**	0.25	0.25	± 90%
Adjustment for partner overlap (heterosexuals) [67]	0.75	0.75	± 25%
Adjustment for partner overlap (MSM)**	not applicable	0.50	± 25%
Additional adjustment for averted HIV costs for MSM**	not applicable	0.25	not varied
HIV cases averted per person counseled and tested [78,81]	0.00045	0.00045	± 90%
Adjustment for repeat counseling and testing**	0.875	0.875	± 10%

*The average sequelae cost per case of syphilis was set equal to the average cost per case of syphilis (and the indirect cost per case of syphilis was set equal to the indirect cost per case of untreated syphilis), because when calculating the costs of syphilis we allowed for the possibility that treatment of syphilis would have occurred (even in the absence of the STI program) before the onset of sequelae.

**See text for sources, assumptions, and additional information.

of the consumer price index for all urban consumers from the US Department of Labor, Bureau of Labor Statistics.

Sequelae costs averted by treatment of people with chlamydia, gonorrhea, and P&S syphilis

Formulas for estimating the sequelae costs averted by treatment of chlamydia and gonorrhea were based on published estimates of the impact of STI treatment on the probability of developing pelvic inflammatory disease (PID) in women or epididymitis in men and the average costs per case of PID and epididymitis. We assumed the probability of PID in women would be reduced from 20% to 4% by treatment of chlamydia [5,10-18] and would be reduced from 20% to 6% by treatment of gonorrhea [5,10,11,13-16,19,20]. We assumed the probability of epididymitis in men would be reduced from 3% to 0% by treatment of gonorrhea or chlamydia [5,10,21,22]. We applied \$1,995 as the direct medical cost per case of PID (the average of three published estimates, \$1,621 [23], \$2,772 [24], and \$1,592 [25]), which includes the costs of care for acute PID and costs associated with sequelae such as chronic pelvic pain, ectopic pregnancy, and infertility. We applied \$274 as the direct medical cost per case of epididymitis [26].

For P&S syphilis in men and women, the average cost averted per case treated we applied was \$572 [5]. This cost includes the possibility of neurosyphilis and cardiovascular syphilis in untreated syphilis cases, and allows for the possibility that treatment of syphilis would have occurred subsequently (either by the infected person seeking treatment or receiving treatment inadvertently through admin-

istration of antibiotics for an unrelated health condition), before the advent of sequelae [5]. We included the possibility of subsequent treatment before the advent of sequelae for syphilis (but not for gonorrhea and chlamydia) because the time span from infection to sequelae can be substantially longer for syphilis than for gonorrhea and chlamydia [5,23].

The number of infected people treated was calculated as the number of treated people with laboratory-confirmed infections, plus Q times the number of treated people with clinical diagnosis of infection, plus R times the number of people treated presumptively because of sexual contact with a partner known or suspected to be infected, where Q and R are defined as follows. Q is the probability that a person with a clinical diagnosis of a given STI is actually infected with that STI. We applied values of Q of 20% for chlamydia and gonorrhea in women, 35% for chlamydia and gonorrhea in men, and 70% for syphilis in men and women, based on published reports of the utility of syndromic diagnoses and the frequency of chlamydia as a cause of male nongonococcal urethritis [27-33]. R is the probability that the sex partner of an infected person is also infected. We applied values of R of 57% for chlamydia and 46% for gonorrhea, based on studies of partner notification [34-36]. We applied a value of R of 30% for syphilis, based on studies of partner notification [35,37-39] as well as estimates of the per-partnership transmission probability of syphilis [40,41].

We also allowed the possibility that people with gonorrhea might be treated presumptively for chlamydia, and

Table 2: Summary of STI program data needed to apply the averted cost formulas

	All women	Heterosexual men	Men who have sex with men
Number of people treated: lab-confirmed infection			
Chlamydia	X ₁	Y ₁	Z ₁
Gonorrhea	X ₂	Y ₂	Z ₂
Syphilis	X ₃	Y ₃	Z ₃
Number of people treated: clinical diagnosis			
Chlamydia	X ₄	Y ₄	Z ₄
Gonorrhea	X ₅	Y ₅	Z ₅
Syphilis	X ₆	Y ₆	Z ₆
Number of partners treated*			
Chlamydia	X ₇	Y ₇	Z ₇
Gonorrhea	X ₈	Y ₈	Z ₈
Syphilis	X ₉	Y ₉	Z ₉
Number treated presumptively for chlamydia, based on gonorrhea diagnosis	X ₁₀	Y ₁₀	Z ₁₀
Number treated presumptively for gonorrhea, based on chlamydia diagnosis	X ₁₁	Y ₁₁	Z ₁₁
Number of people receiving HIV counseling and testing	X ₁₂	Y ₁₂	Z ₁₂
Number of pregnant women treated for syphilis, lab-confirmed diagnosis	X ₁₃	not applicable	not applicable
Number of pregnant women treated for syphilis, clinical diagnosis	X ₁₄	not applicable	not applicable
Number of pregnant women treated for syphilis, partner notification	X ₁₅	not applicable	not applicable

*Refers to those treated because of sexual contact with an infected person. For example, X₇ refers to the number of women treated for chlamydia because of sexual contact with an infected person. Syphilis cases include primary and secondary (P&S) syphilis only.

Table 3: Summary of the estimated numbers of infected people treated for sexually transmitted infections

Symbol	Description	Formula
C_w	Number of women with chlamydia treated	$X_1 + 0.2(X_4) + 0.57(X_7) + 0.42(X_{10})$
\hat{C}_w	Number of women with chlamydia treated, excluding partner services	$X_1 + 0.2(X_4) + 0.42(X_{10})$
C_m	Number of heterosexual men with chlamydia treated	$Y_1 + 0.35(Y_4) + 0.57(Y_7) + 0.2(Y_{10})$
\hat{C}_m	Number of heterosexual men with chlamydia treated, excluding partner services	$Y_1 + 0.35(Y_4) + 0.2(Y_{10})$
C_{msm}	Number of MSM with chlamydia treated	$Z_1 + 0.35(Z_4) + 0.57(Z_7) + 0.2(Z_{10})$
\hat{C}_{msm}	Number of MSM with chlamydia treated, excluding partner services	$Z_1 + 0.35(Z_4) + 0.2(Z_{10})$
G_w	Number of women with gonorrhoea treated	$X_2 + 0.2(X_5) + 0.46(X_8) + 0.15(X_{11})$
\hat{G}_w	Number of women with gonorrhoea treated, excluding partner services	$X_2 + 0.2(X_5) + 0.15(X_{11})$
G_m	Number of heterosexual men with gonorrhoea treated	$Y_2 + 0.35(Y_5) + 0.46(Y_8) + 0.15(Y_{11})$
\hat{G}_m	Number of heterosexual men with gonorrhoea treated, excluding partner services	$Y_2 + 0.35(Y_5) + 0.15(Y_{11})$
G_{msm}	Number of MSM with gonorrhoea treated	$Z_2 + 0.35(Z_5) + 0.46(Z_8) + 0.15(Z_{11})$
\hat{G}_{msm}	Number of MSM with gonorrhoea treated, excluding partner services	$Z_2 + 0.35(Z_5) + 0.15(Z_{11})$
S_w	Number of women with syphilis treated	$X_3 + 0.7(X_6) + 0.3(X_9)$
\hat{S}_w	Number of women with syphilis treated, excluding partner services	$X_3 + 0.7(X_6)$
S_m	Number of heterosexual men with syphilis treated	$Y_3 + 0.7(Y_6) + 0.3(Y_9)$
\hat{S}_m	Number of heterosexual men with syphilis treated, excluding partner services	$Y_3 + 0.7(Y_6)$
S_{msm}	Number of MSM with syphilis treated	$Z_3 + 0.7(Z_6) + 0.3(Z_9)$
\hat{S}_{msm}	Number of MSM with syphilis treated, excluding partner services	$Z_3 + 0.7(Z_6)$

The X_i , Y_i , and Z_i terms are defined in Table 2. Syphilis cases include primary and secondary (P&S) syphilis only.

vice-versa. To incorporate this possibility, we assumed that 20% and 42% of men and women, respectively, with gonorrhoea who were treated presumptively for chlamydia did indeed have chlamydia, based on a study of coinfection in STI clinic attendees in the US [42] and consistent with coinfection studies in other settings [43-49]. We assumed that 15% of men and women with chlamydia who were treated presumptively for gonorrhoea did indeed have gonorrhoea [42-48].

Regardless of the reason for treatment (laboratory-confirmed diagnosis, clinical diagnosis, partner services, or presumptive treatment for dual infection) for gonorrhoea and chlamydia, we reduced the estimated impact of treatment by multiplying by two adjustment factors. The first adjustment factor (0.925 for men and women treated for chlamydia, and 0.79 and 0.9 for women and men, respectively, treated for gonorrhoea) was based on the probability of gonorrhoea and chlamydia coinfection described above and was included to mitigate potential overestimation of the benefits of preventing PID or epididymitis in people with both gonorrhoea and chlamydia. The second adjustment factor (0.70 for men and women treated for gonorrhoea, chlamydia, or both) was included to account for the possibility of re-infection within one year of treatment [50-62], which could offset (at least partially) the benefits of treatment.

Estimates of the number of treated partners may be unavailable in the event of patient-delivered partner therapy. In such cases, a reasonable approximation is that, on average, one partner is treated for each patient provided with therapy for his or her partner(s) [53]. This average reflects

the possibility that some patients might give the medication to none, one, or more than one of their partners.

Congenital syphilis treatment costs averted by treatment of P&S syphilis in women

We assumed that in the absence of treatment, 50% of pregnant women with P&S syphilis would have delivered a child with congenital syphilis [63]. The first-year direct medical cost estimate we applied for congenital syphilis was \$6,738 [1,64,65]. The estimated averted costs are likely understated because we did not assign a cost to premature births and stillbirths, or costs of congenital syphilis beyond one year.

Treatment and sequelae costs averted by reducing transmission of chlamydia, gonorrhoea, and syphilis in the population

We assumed that each STI case treated prevents, on average, 0.5 cases of that STI in the population by interrupting the transmission of that STI. This assumption is based in part on a model-based evaluation of chlamydia screening, in which the estimated number of adverse outcomes prevented when the population-level benefits of screening were addressed was roughly double the estimated number of adverse outcomes prevented when population-level benefits were not modeled [66]. These modeling results are consistent with an assumption that each STI case treated would prevent, on average, one additional case of that STI in the population. However, to account for possible overlap in the sex partners of people treated [67] and the possibility that secondary transmission(s) from the infected person had already occurred prior to treatment, we reduced the expected population-level impact by 50%,

Table 4: Formulas for estimating averted direct medical costs of chlamydia, gonorrhea, syphilis, and congenital syphilis

Sequelae costs averted by treatment of people with chlamydia, gonorrhea, and syphilis	
Chlamydia	$[(C_w)(0.16)(0.925)(0.70)(\$1,995)] + [(C_m + C_{msm})(0.03)(0.925)(0.70)(\$274)]$
Gonorrhea	$[(G_w)(0.14)(0.79)(0.70)(\$1,995)] + [(G_m + G_{msm})(0.03)(0.90)(0.70)(\$274)]$
Syphilis	$(S_w + S_m + S_{msm})(\$572)$
Congenital syphilis treatment costs averted by treatment of syphilis in women	
	$[X_{13} + 0.7(X_{14}) + 0.3(X_{15})] [(0.5)(\$6,738)]$
Treatment and sequelae costs averted by reducing transmission of chlamydia, gonorrhea, and syphilis in the population	
Chlamydia	$[(\hat{C}_w + \hat{C}_m)(0.5)(\$171)] + [(\hat{C}_{msm})(0.5)(\$26)]$
Gonorrhea	$[(\hat{G}_w + \hat{G}_m)(0.5)(\$206)] + [(\hat{G}_{msm})(0.5)(\$68)]$
Syphilis	$(\hat{S}_w + \hat{S}_m + \hat{S}_{msm})(0.5)(\$572)$

The C_i , G_i , S_i , \hat{C}_i , \hat{G}_i , and \hat{S}_i terms are defined in Table 3. The X_i , Y_i , and Z_i terms are defined in Table 2. Syphilis cases include primary and secondary (P&S) syphilis only.

thereby assuming that each case of STI treated prevents 0.5 cases (rather than one case) of that STI in the population.

To calculate the treatment and sequelae costs averted by the interruption of STI transmission, we applied published estimates of the average lifetime cost per case of syphilis, gonorrhea, and chlamydia, as these estimates incorporate the probability and cost of STI treatment as well as the probability and cost of adverse sequelae in the absence of treatment. The estimated average lifetime direct medical costs per case we applied were: \$315 and \$26 for chlamydia in women and men, respectively; \$343 and \$68 for gonorrhea in women and men, respectively, and \$572 for syphilis in men and women [5]. The average treatment and sequelae cost per case of syphilis we applied (\$572) was the same value we applied above for the sequelae cost averted per case of syphilis treated, because when calculating the sequelae cost of syphilis averted by treatment we allowed for the possibility of subsequent treatment for syphilis before the advent of sequelae.

In assessing the costs averted by the interruption of STI transmission by treatment of STIs in heterosexuals, we applied the average cost per case of that STI in women and men (\$171 for chlamydia, \$206 for gonorrhea, and \$572 for syphilis), because treatment of a person with a given STI would be expected to reduce treatment and sequelae costs not only in his or her opposite-sex partners, but in the partners' subsequent opposite-sex partners as well, and so on. In assessing the costs averted by the interruption of STI transmission by treatment of STIs in men who have sex with men (MSM), we applied the STI costs per case in men.

In developing the formula for costs averted through the interruption of STI transmission, we excluded people treated for STIs as a result of partner notification, to reduce potential double-counting of the benefits of preventing STIs in partners of infected people treated for STIs.

HIV costs averted by reducing HIV transmission through treatment of chlamydia, gonorrhea, and P&S syphilis

Because STIs can facilitate the acquisition and transmission of HIV [68], treatment of STIs can reduce the incidence of HIV [69]. Thus, treatment of STIs offer the additional economic benefit of reducing HIV costs as well [70].

The average number of HIV cases attributable to each new case of chlamydia, gonorrhea, and P&S syphilis in heterosexuals has been estimated at 0.0011, 0.0007, and 0.02386, respectively [70]. These estimates are based on the facilitative effects of the STI on HIV transmission and acquisition from the time of acquisition of the STI. We assumed that the treatment of the STI reduces the time frame in which an STI-attributable HIV transmission is possible by one-fourth. That is, in terms of preventing STI-attributable HIV cases, we assumed that treating an STI provided only one-fourth the potential benefit of preventing the STI altogether. Thus, the above-listed probabilities were multiplied by 0.25 in our application. The resulting estimate was then multiplied by 0.75 to account for overlap in sex partners [67] of people treated by a given STI program.

For the expected number of STI-attributable HIV infections per case of STI in MSM, we applied the same estimates as above for heterosexuals, except that we applied an adjustment factor of 0.50 (rather than 0.75) to account for partner overlap, owing to higher numbers of casual and anonymous partners in MSM at high risk for STIs and HIV than in heterosexual men [37,71-75]. We applied an additional adjustment factor of 0.25 for MSM because, in populations at high risk of acquiring HIV, a substantial proportion of the estimated HIV cases prevented may actually be "delayed" rather than "forever averted" by prevention efforts [76], and to account for "HIV sero-sorting" in which partners are selected based on HIV status [77].

In developing the formula for costs averted by preventing STI-attributable HIV infections, we excluded people

Table 5: Formulas for estimating averted direct medical costs of HIV

HIV costs averted by reducing HIV transmission through treatment of chlamydia, gonorrhoea, and syphilis	
Chlamydia	$[(\hat{C}_w + \hat{C}_m)(0.0011)(0.25)(0.75)(\$198,471)] + [(\hat{C}_{msm})(0.0011)(0.25)(0.50)(0.25)(\$198,471)]$
Gonorrhoea	$[(\hat{G}_w + \hat{G}_m)(0.0007)(0.25)(0.75)(\$198,471)] + [(\hat{G}_{msm})(0.0007)(0.25)(0.50)(0.25)(\$198,471)]$
Syphilis	$[(\hat{S}_w + \hat{S}_m)(0.02386)(0.25)(0.75)(\$198,471)] + [(\hat{S}_{msm})(0.02386)(0.25)(0.50)(0.25)(\$198,471)]$
HIV costs averted by HIV counseling and testing	
	$[(X_{12} + Y_{12})(0.00045)(0.75)(0.875)(\$198,471)] + [(Z_{12})(0.00045)(0.50)(0.25)(0.875)(\$198,471)]$

The C_i , G_i , S_i , \hat{C}_i , \hat{G}_i , \hat{S}_i terms are defined in Table 3. The X_i , Y_i , and Z_i terms are defined in Table 2. Syphilis cases include primary and secondary (P&S) syphilis only.

treated for STIs as a result of partner notification, to reduce potential double-counting of the benefits of preventing STI-attributable HIV infections in partners of infected people treated for STIs.

We applied a lifetime direct medical cost per case of HIV of \$198,471 for both men and women [6].

HIV costs averted by HIV counseling and testing

HIV counseling and testing can reduce HIV incidence by reducing not only the probability that a person with HIV will transmit the virus (through behavioral changes due to counseling and virologic effects of antiretroviral therapy), but also the probability that a person without HIV will become infected [78-80]. One published decision analysis model suggested that HIV counseling and testing, when provided to a cohort of 10,000 people with 1.5% HIV seroprevalence, would avert 8 cases of HIV [78]. Another published model suggested that roughly 1 case of HIV would be prevented per 10,000 people screened [81]. We applied the average of these two estimates, thereby assuming that an expected 0.00045 cases of HIV are averted for each person counseled and tested. As described above, we applied an adjustment to account for partner overlap (0.75 for heterosexuals and 0.5 for MSM), and a further adjustment factor (0.25) for MSM to account for sero-sorting in the absence of counseling and testing and for the possibility that HIV infections prevented are not forever averted but merely delayed. We also applied an additional adjustment factor (0.875) to mitigate the double-counting of benefits in people seeking repeat counseling and testing [82,83].

As the incidence of HIV in populations served by counseling and testing programs can exceed 1% annually [84], only modest reductions in HIV risk behaviors would be needed to achieve the per-person reduction in HIV incidence we applied in this exercise.

Indirect costs (lost productivity) averted

Our estimates of the indirect costs of STIs focused on lost productivity. The lost productivity per case of HIV has been estimated at \$831,614 [6]. The lost productivity per case of untreated chlamydia in females has been estimated at \$148 [85]. To our knowledge, estimates of the

lost productivity associated with untreated STIs were not available for chlamydia in males, and for gonorrhoea and syphilis in males and females at the time this study was conducted. For these STIs, we assumed that the ratio of indirect costs per untreated case to lifetime direct medical costs per case was 0.5, roughly the same as for chlamydia in females (\$148/\$315). The use of such ratios to estimate indirect costs is based on the assumption that indirect and direct costs of a given disease are usually related to the severity of the disease. Ratios of indirect to direct costs consistent with our assumption of 0.5 have been applied elsewhere in other studies of the burden of STIs [86].

Using this 0.5 ratio, the estimated lost productivity per case of untreated STI was as follows: \$13 for chlamydia in men; \$171 and \$34 for gonorrhoea in women and men, respectively; and \$286 for syphilis in men and women. The indirect cost for congenital syphilis using this formula is \$3,369. However, to incorporate potentially lifelong impacts of congenital syphilis, we assumed this indirect cost of \$3,369 was incurred every year for 25 years, for a total indirect cost of \$60,421 (when applying a 3% annual discount rate).

The indirect costs estimates listed above for chlamydia, gonorrhoea, and syphilis reflect the average cost per untreated case. For the purposes of this exercise, we also needed estimates of the average cost per case of chlamydia, gonorrhoea, and syphilis that incorporate the probability of receiving treatment and avoiding sequelae-related indirect costs. To calculate estimates of the average indirect costs per case of STI, we applied the following probabilities of receiving treatment before the possible onset of sequelae: 68% and 22% for women and men, respectively, with chlamydia; 73% and 71% for women and men, respectively, with gonorrhoea, and 61% for men and women with syphilis [5]. We conservatively assumed that treatment for STIs before the onset of sequelae imposed no indirect costs. Under these assumptions, the estimated indirect costs per case of STI were approximately as follows: \$47 for chlamydia and gonorrhoea in women, \$10 for chlamydia and gonorrhoea in men, and \$112 for syphilis in men and women. In keeping with our assumption applied earlier that subsequent treatment of syphilis might occur before the onset of sequelae, we applied the

same value (\$112) for the indirect cost per case of syphilis and the indirect cost per untreated case of syphilis (Table 1).

We applied the indirect costs per case of STI for cases averted by the interruption of STI transmission in the population. For partners of heterosexuals, we applied the average indirect cost per case averted in men and women (\$29 for chlamydia and gonorrhea, reflecting the average indirect cost per case of \$47 in women and \$10 in men, and \$112 for syphilis). For partners of MSM, we applied the indirect cost per case in men (\$10 for chlamydia and gonorrhea, and \$112 for syphilis).

In calculating the indirect costs averted by treating people with STIs, we applied the estimated indirect cost per untreated case of STI.

Sensitivity analyses

To address the uncertainty in the cost per case estimates and other parameter values, we applied a range of values as indicated in Table 1. We used Monte Carlo simulations [87] to generate a range of the most plausible estimates of the costs averted by STI prevention. We performed 50,000 simulations, each time drawing a random value for each parameter, assuming a triangular distribution between the parameter's lower and upper bound values. For each simulation, we calculated the relative change in the direct costs averted (the percentage difference between the averted direct costs in the simulation and the averted direct costs in the base case). For each simulation, we also calculated the relative change in the indirect costs averted, which for simplicity we calculated as the average of the relative change in indirect costs averted in treated people and the relative change in indirect costs averted in partners of treated people. We then used the 10th and 90th percentiles of these 50,000 simulations as the lower and upper bound values of the STI costs averted by STI program activities.

Examples of averted cost calculations

To illustrate the use of the formulas, we examined the estimated costs averted by the treatment of 1,000 people with chlamydia, 500 people with gonorrhea, and 100 people with syphilis, assuming that everyone treated had a laboratory-confirmed infection. We also estimated the costs averted by HIV counseling and testing of 2,000 people. In all of these examples, we assumed that 60% of those served were men, and that 67% of the men were heterosexual.

Results

The input needed from the STI program in order to apply the averted cost formulas is summarized in Table 2. The formulas to estimate the numbers of infected people treated for chlamydia, gonorrhea, and P&S syphilis are summarized in Table 3. The formulas used to estimate the averted costs (in 2006 US dollars) are presented in Tables 4, 5, 6.

Sequelae costs averted by treatment of people with chlamydia, gonorrhea, and P&S syphilis (Table 4, top)

For chlamydia, the formula includes the absolute reduction in the probability of sequelae associated with treatment (0.16 for women and 0.03 for men), the sequelae cost (\$1,995 for women and \$274 for men), an adjustment (0.925) to prevent double-counting of benefits of treating people with both gonorrhea and chlamydia, and an adjustment (0.70) to account for the possibility of re-infection. For gonorrhea, the formula includes the absolute reduction in the probability of sequelae associated with treatment (0.14 for women and 0.03 for men), the sequelae cost (\$1,995 for women and \$274 for men), an adjustment (0.79 for women and 0.9 for men) to prevent double-counting of benefits of treating people with both gonorrhea and chlamydia, and an adjustment (0.70) to account for the possibility of re-infection. For syphilis, the formula includes the cost per case of syphilis (\$572).

Table 6: Formulas for estimating averted indirect costs (lost productivity) of chlamydia, gonorrhea, syphilis, congenital syphilis, and HIV

Indirect STI costs averted	
Chlamydia	$[(C_w)(0.925)(0.70)(\$148)] + [(C_m + C_{msm})(0.925)(0.70)(\$13)] + [(\hat{C}_w + \hat{C}_m)(0.5)(\$29)] + [(\hat{C}_{msm})(0.5)(\$10)]$
Gonorrhea	$[(G_w)(0.79)(0.70)(\$171)] + [(G_m + G_{msm})(0.9)(0.70)(\$34)] + [(w + m)(0.5)(\$29)] + [(msm)(0.5)(\$10)]$
Syphilis	$[(S_w + S_m + S_{msm})(\$112)] + [(\hat{S}_w + \hat{S}_m + \hat{S}_{msm})(0.5)(\$112)]$
Congenital syphilis	$[X_{13} + 0.7(X_{14}) + 0.3(X_{15})] [(0.5)(\$60,421)]$
Indirect HIV costs averted by reducing HIV transmission through treatment of STIs	
Chlamydia	$[(\hat{C}_w + \hat{C}_m)(0.0011)(0.25)(0.75)(\$831,614)] + [(\hat{C}_{msm})(0.0011)(0.25)(0.5)(0.25)(\$831,614)]$
Gonorrhea	$[(w + m)(0.0007)(0.25)(0.75)(\$831,614)] + [(msm)(0.0007)(0.25)(0.5)(0.25)(\$831,614)]$
Syphilis	$[(\hat{S}_w + \hat{S}_m)(0.02386)(0.25)(0.75)(\$831,614)] + [(\hat{S}_{msm})(0.02386)(0.25)(0.5)(0.25)(\$831,614)]$
Indirect HIV costs averted by reducing HIV transmission through HIV counseling and testing	
	$[(X_{12} + Y_{12})(0.00045)(0.75)(0.875)(\$831,614)] + [(Z_{12})(0.00045)(0.50)(0.25)(0.875)(\$831,614)]$

The C_i, G_i, S_i, C_i, i, and S_i terms are defined in Table 3. The X_i, Y_i, and Z_i terms are defined in Table 2. Syphilis cases include primary and secondary (P&S) syphilis only.

Table 7: Ranges of estimates of costs averted by STI programs: sensitivity analyses

Cost estimated	Upper and lower bounds obtained in simulations (10 th and 90 th percentiles)
Sequelae costs averted by treatment of people with chlamydia and gonorrhea	Base case - 54%, Base case + 60%
Sequelae costs averted by treatment of people with syphilis	Base case - 28%, Base case + 28%
Congenital syphilis treatment costs averted	Base case - 36%, Base case + 39%
Treatment and sequelae costs averted by reducing STIs in the population	Base case - 53%, Base case + 58%
HIV costs averted through treatment of STIs	Base case - 67%, Base case + 80%
HIV costs averted by HIV counseling and testing	Base case - 54%, Base case + 60%
Indirect chlamydia and gonorrhea costs averted	Base case - 35%, Base case + 38%
Indirect syphilis costs averted	Base case - 35%, Base case + 38%
Indirect congenital syphilis costs averted	Base case - 36%, Base case + 39%
Indirect HIV costs averted through treatment of STIs	Base case - 67%, Base case + 80%
Indirect HIV costs averted by HIV counseling and testing	Base case - 54%, Base case + 60%

Congenital syphilis treatment costs averted by treatment of P&S syphilis in women (Table 4, middle)

These formulas include the terms 0.7 and 0.3 to represent the probability that women in the specific categories actually have syphilis. The term 0.5 reflects the probability of congenital syphilis in the absence of treatment, and the term \$6,738 represents the direct medical cost of congenital syphilis.

Treatment and sequelae costs averted by reducing transmission of chlamydia, gonorrhea, and syphilis in the population (Table 4, bottom)

In these formulas, the term 0.5 represents the number of cases of STI averted in the population per person treated for that STI. The average lifetime cost per case of STI is given by the terms \$171 and \$26 (for chlamydia in partners of heterosexuals and MSM, respectively) and \$206 and \$68 (for gonorrhea in partners of heterosexuals and MSM, respectively), and \$572 (for syphilis).

HIV costs averted by reducing HIV transmission through treatment of chlamydia, gonorrhea, and P&S syphilis (Table 5, top)

These formulas include the probability that an STI-attributable HIV infection will occur per new case of STI (0.0011 for chlamydia, 0.0007 for gonorrhea, and 0.02386 for syphilis), an adjustment (0.25) reflecting the assumption that (in terms of preventing STI-attributable HIV infections) treating an STI provides only one-fourth the benefit of preventing the STI altogether, an adjustment to account for partner overlap (0.75 for heterosexuals and 0.5 for MSM), a further adjustment (0.25) for MSM to account for sero-sorting and for the possibility that HIV infections prevented are not forever averted but merely delayed, and the cost per case of HIV (\$198,471).

HIV costs averted by HIV counseling and testing (Table 5, bottom)

These formulas include the reduction in the probability of acquiring or transmitting HIV (0.00045), adjustment factors to account for partner overlap (0.75 for heterosexuals and 0.5 for MSM), a further adjustment for MSM (0.25) as described above, an adjustment to mitigate the double-counting of benefits in people seeking repeat counseling and testing (0.875), and the cost per case of HIV (\$198,471).

Indirect costs (lost productivity) averted (Table 6)

The formulas for the indirect STI costs averted include two main components. First, there are the benefits of treating people for STIs, calculated using the indirect cost per untreated case (\$148 and \$13 for chlamydia in women and men, \$171 and \$34 for gonorrhea in women and men, and \$112 for syphilis in women and men). The adjustment terms 0.925 (for chlamydia), 0.79 and 0.90 (for gonorrhea in women and men, respectively) are applied to prevent double-counting of benefits of treating people with both gonorrhea and chlamydia. The adjustment term (0.70) accounts for the possibility of re-infection, which would reduce the benefits of treatment. Second, there are the benefits of preventing STIs in the population, calculated using the indirect cost per case estimates (\$29 for chlamydia and gonorrhea averted in partners of heterosexuals, \$10 for chlamydia and gonorrhea averted in partners of MSM, and \$112 for syphilis in partners of heterosexuals and MSM). The 0.5 term is applied to reflect the expected number of STI infections averted in the population per person treated for a given STI.

The indirect cost formulas for congenital syphilis and HIV are the same as for the direct costs for these two items, except that the estimated indirect cost per case estimates

(\$60,421 for congenital syphilis and \$831,614 for HIV) are applied rather than the direct cost estimates.

Sensitivity analyses (Table 7)

The ranges of estimates for the costs averted by STI programs are shown in Table 7 as a function of the base case results. These ranges show the estimated 10th and 90th percentile of averted cost estimates that would result in 50,000 simulations in which the inputs in Table 1 were simultaneously varied between their lower and upper bounds (assuming a triangular distribution). Sequelae costs averted by treatment of people with chlamydia and gonorrhea varied substantially, owing primarily to uncertainty in the probability of sequelae in the absence of treatment. Treatment and sequelae costs averted by reducing STIs in the population varied substantially as well, given the uncertainty in estimating the population-level benefits of STI treatment of individuals. HIV costs averted varied more than any other category of costs, due in part to the uncertainty in the probability of averting a new case of HIV.

Examples of averted cost calculations (Table 8)

For the four hypothetical program activities in our example, the estimates of the averted costs ranged from \$165,030 to \$575,360. The highest estimate (\$575,360) was obtained for the syphilis treatment scenario, despite the lower number of people treated (100) in this scenario. The estimate of the costs averted per person served in this scenario was notably higher than the other scenarios, and can be attributed to three main factors: the lifetime cost per case estimate we applied for syphilis was higher than that of gonorrhea or chlamydia, the benefits of preventing congenital syphilis were included, and, most importantly, the probability of an STI-attributable HIV infection was higher for syphilis than for gonorrhea and chlamydia.

Discussion

The formulas developed in this study can be a useful tool to STI program personnel to generate evidence-based estimates of the economic impact of their program. The estimates generated by these formulas, when combined with estimates of program costs, can provide estimates of the net cost (program costs minus costs averted by program activities) of a program. Such estimates might be of value for those who want simply to compare the costs averted by their program to the overall budget of their program, as well as to those who want to develop estimates of the cost-effectiveness of their program activities. However, providing guidance for estimating the program costs of a specific STI prevention activity (such as STI screening in correctional settings) is beyond the scope of this manuscript.

The formulas we present are not reduced to more basic forms. For example, in the first formula in Table 4, the term "(0.16)(0.925)(0.70)(\$1,995)" is not reduced to "\$207." We presented the formulas in this manner to facilitate adaptation of these formulas to non-US settings, or in US settings with substantially different input values, such as for the reduction in probability of PID associated with chlamydia treatment (0.16) or the direct medical costs associated with PID (\$1,995). Presentation of the formulas in their longer forms allows for easier substitution of parameter values. We have developed a spreadsheet-based tool (available from the authors upon request) to facilitate the application of these formulas.

In the event that information on the sexual orientation of men served by a given program is unavailable or unreliable, estimates on the number of heterosexual men and MSM treated for each STI can be estimated based on the male-female ratio of STI cases in the population served by the program [88]. In a simplified application of the approach used by Heffelfinger and colleagues [88], the

Table 8: Examples of estimated costs averted by STI program activities

Costs averted	Chlamydia treatment (1,000 people)	Gonorrhea treatment (500 people)	Syphilis treatment (100 people)	HIV C&T (2,000 people)
Direct costs averted				
STI sequelae costs in treated people	\$85,870	\$32,440	\$57,200	\$0
Congenital syphilis costs	\$0	\$0	\$8,890	\$0
Population-level STI costs	\$71,010	\$44,610	\$28,600	\$0
STI-attributable HIV costs	\$34,120	\$10,860	\$74,010	\$0
HIV costs averted through C&T	\$0	\$0	\$0	\$97,700
Indirect costs averted				
Indirect STI costs	\$55,980	\$31,640	\$96,560	\$0
Indirect HIV costs	\$142,960	\$45,490	\$310,100	\$409,390
Total costs averted	\$389,950	\$165,030	\$575,360	\$507,100

HIV C&T: HIV counseling and testing. Indirect HIV costs averted include the costs averted through prevention of STI-attributable HIV cases. Total costs may not match sum of direct and indirect costs due to rounding.

number of cases of a given STI in MSM can be estimated as the number of cases of that STI in men minus the number of cases of that STI in women (assuming there are more cases in men than in women).

In the event that information on the number of pregnant women treated for P&S syphilis is not known, this number can be estimated as the number of infected women treated for P&S syphilis (S_w) multiplied by an adjustment factor to reflect the birth rate. For example, the adjustment term 0.066 could be applied in US settings, to reflect the birth rate among women ages 15 to 44 years in the US in 2004 (66 live births per 1,000 women) [89].

The formulas related to syphilis presented in Tables 1, 2, 3, 4, 5, 6 focus on P&S syphilis. The benefits of treatment of early latent syphilis cases could be included easily, by multiplying the number of early latent syphilis cases treated by the direct cost per case of syphilis (\$572) and by the indirect cost per case of syphilis (\$112). This adjustment conservatively assumes no benefit of treating early latent syphilis in terms of interrupting syphilis transmission, preventing congenital syphilis, and reducing HIV transmission.

Key sources of uncertainty

There is uncertainty in the probability of PID in the absence of treatment for chlamydia and gonorrhea. We applied a 20% probability, which is in the lower portion of the often-cited range of 10% to 40% [5]. Nonetheless, it is possible that this 20% value overstates the probability of developing PID [90]. In light of the uncertainty in the probability of developing PID, we applied a cost per case of PID that falls in the lower end of the range of plausible values [23-25].

The average sequelae costs averted by syphilis treatment are not known with precision. To account for this uncertainty, we assumed that people with syphilis not treated by the STI program might seek treatment for syphilis elsewhere, or receive treatment inadvertently through antibiotics administered for an unrelated condition. This assumption reduced the expected sequelae costs of untreated syphilis by more than half, thereby making the estimates of the costs averted by syphilis treatment more conservative.

The formula for estimating the value of the interruption of STI transmission in the population applies an assumption that each case treated prevents 0.5 cases of that STI in the population. This assumption, though somewhat arbitrary, is likely conservative, because STI rates would decline if each new STI infection caused less than one more new infection [91]. In reality, reported rates of chlamydia, gon-

orrhoea, and P&S syphilis in the US increased slightly in 2005 [92].

The formulas for estimating the reduction in STI-attributable HIV infections and for estimating the number of HIV infections averted by HIV counseling and testing are based on simple models, and may be more applicable for certain areas than others depending on factors such as HIV prevalence and HIV co-infection in people with STIs. However, the adjustments we applied (to account for partner overlap, for the impact of treatment on the interval in which an STI-attributable HIV infection might occur, and for the possibility that HIV cases averted are merely "delayed" rather than "forever averted") greatly reduced the estimated impact of program activities on HIV incidence. Of note, the probability of an STI-attributable HIV infection we applied for syphilis was substantially higher than that of gonorrhoea or chlamydia. In the study from which these estimates were obtained, more conservative assumptions regarding the probability of HIV/STI coinfection were applied for gonorrhoea and chlamydia than for syphilis, owing to the relatively plentiful studies of syphilis and HIV coinfection [70,93]. As such, the benefit of treating people with syphilis (relative to the benefit of treating people with gonorrhoea or chlamydia) may be overestimated.

There is uncertainty in the indirect cost per case estimates, particularly in the instances when such estimates were not available from the literature and were calculated assuming an 0.5 ratio of indirect costs to direct medical costs per case (similar to that reported for the indirect cost of untreated chlamydia in females). The limited number of available estimates of indirect STI costs highlights the need for future studies in this area. Our estimates of the indirect costs included only lost productivity and excluded other indirect costs (such as foregone leisure time and time spent by family and friends for hospital visits). Thus, the indirect cost estimates we applied may be conservative. For example, the indirect cost estimate we applied for congenital syphilis (\$60,421) was substantially more conservative than that of a 1983 study which estimated the lifetime cost of special educational needs and reduced productivity per case of congenital syphilis at over \$200,000 [94].

Clearly, estimating the economic impact of STI programs is an inexact exercise. However, to address the inherent uncertainty, we made numerous conservative assumptions as discussed above, such as applying a cost of PID in the lower range of plausible values, adjusting for partner overlap when estimating the impact of program activities on STI and HIV transmission, and assuming less impact of STI treatment on population-level STI incidence than would be expected given recent trends in reported STI

rates in the US. The direct costs we applied for congenital syphilis and syphilis in adults were more conservative than the burden suggested in a cost-effectiveness study of a corrections-based syphilis screening program [95]. Furthermore, the calculations presented here may substantially understate the benefits of STI program activities because (1) not all of the potential benefits of treating people with chlamydia, gonorrhea, and P&S syphilis are included; (2) the benefits of preventing other STIs (such as genital herpes, human papillomavirus, hepatitis B, and trichomoniasis) are not included; and (3) we did not include intangible costs such as pain and suffering, which can be considerable.

Resource allocation implications

The formulas presented here are intended to assist in the estimation of the economic impact of STI programs. Although the estimates resulting from these formulas can provide information relevant to resource allocation decisions, these formulas are not intended as a resource allocation tool, per se. First, our estimates of the costs averted by preventing a given STI may be overstated relative to the costs averted by preventing another STI. For example, as discussed above, the STI-attributable HIV costs for gonorrhea and chlamydia are more conservative than for syphilis. Second, our model is static and does not account for diminishing marginal returns. That is, in our model the benefits of STI treatment are constant regardless of the number of people treated. In reality, when prevention efforts are focused more intensely on one specific STI or on one specific population, the marginal benefits of prevention efforts would be expected to decrease (at some point). These limitations, as well as the uncertainties described above, should be considered when determining the utility of these formulas for informing resource allocation decisions.

Conclusion

We provide a series of formulas that STI programs can use to generate estimates of the economic impact of their program activities, based primarily on published studies of the costs of STIs, the impact of STIs on HIV transmission, and the impact of HIV counseling and testing on HIV incidence. A spreadsheet-based tool to facilitate the application of these formulas is available from the authors upon request.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

DC and HWC originated the study. All authors participated in its design and in the development of assumptions on which the resulting formulas are based. HWC constructed the formulas and drafted the manuscript. All

authors contributed to revisions of the manuscript, and read and approved the final manuscript.

Acknowledgements

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

The authors thank John Beltrami, MD, Robert Johnson, MD, and Lori Newman, MD, for helpful suggestions.

References

1. Chesson HW, Gift TL, Pulver ALS: **The economic value of reductions in gonorrhea and syphilis incidence in the United States, 1990-2003.** *Prev Med* 2006, **43**:411-415.
2. Weinstock H, Berman S, Cates Jr. W: **Sexually transmitted diseases in American youth: incidence and prevalence estimates.** *Perspect Sex Reprod Health* 2004, **36**:6-10.
3. Siegel JE: **Estimates of the economic burden of STDs: Review of the literature with updates.** In *The Hidden Epidemic: Confronting Sexually Transmitted Diseases* Edited by: Eng TR and Butler WT. Washington, DC, National Academy Press; 1997:330-356.
4. Association ASH: *Sexually Transmitted Diseases in America: How Many Cases and at What Cost?* Edited by: Alexander LL, Cates JR, Herndon N and Ratcliffe JF. Menlo Park, CA, Kaiser Family Foundation; 1998.
5. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL: **The estimated direct medical cost of sexually transmitted diseases among American youth, 2000.** *Perspect Sex Reprod Health* 2004, **36**:11-19.
6. Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, del Rio C, Kamimoto L, Kellerman SE: **The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences.** *J Acquir Immune Defic Syndr* 2006, **43**:451-457.
7. Control CD: **Cost-benefit ratios of prevention.** In *STD-HIV Interchange* Atlanta, GA, Centers for Disease Control; 1992.
8. Gold MR, Siegal JE, Russell LB, Weinstein MC: *Cost-Effectiveness in Health and Medicine* Edited by: Gold MR, Siegal JE, Russell LB and Weinstein MC. New York, Oxford University Press; 1996.
9. Haddix AC, Teutsch SM, Corso PS: *Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation* 2nd edition. Edited by: Haddix AC, Teutsch SM and Corso PS. New York, Oxford University Press; 2002.
10. Washington AE, Johnson RE, Sanders LL Jr.: **Chlamydia trachomatis infections in the United States: what are they costing us?** *JAMA* 1987, **257**:2070-2072.
11. Tait IA, Duthie SJ, Taylor-Robinson D: **Silent upper genital tract chlamydia infection and disease in women.** *Int J STD AIDS* 1997, **8**:329-331.
12. **Recommendations for the prevention and management of Chlamydia trachomatis infections, 1993.** Centers for Disease Control and Prevention. *MMWR Recomm Rep* 1993, **42**(RR-12):1-39.
13. Rees E: **The treatment of pelvic inflammatory disease.** *Am J Obstet Gynecol* 1980, **138**:1042-1047.
14. Douglas JM Jr., Newman D, Bolan G, Zenilman JM, Rogers J, Rhodes F, Kamb M, Peterman T: **Low rate of pelvic inflammatory disease (PID) among women with incident Chlamydia trachomatis (CT) infection.** *Int J STD AIDS* 2001, **12**:65-67.
15. Haddix AC, Hillis SD, Kassler WJ: **The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women.** *Sex Transm Dis* 1995, **22**:274-280.
16. Wiesenfeld HC, Hillier SL, Krohn MA, Amortegui AJ, Heine RP, Landers DV, Sweet RL: **Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease.** *Obstet Gynecol* 2002, **100**:456-463.
17. Hook EW III, Spitters C, Reichart CA, Neumann TM, Quinn TC: **Use of cell culture and a rapid diagnostic assay for Chlamydia trachomatis screening.** *JAMA* 1994, **272**:867-870.
18. Bachmann L, Richey CM, Waites K, Schwebke JR, Hook EW III: **Patterns of Chlamydia trachomatis testing and follow-up at a university hospital medical center.** *Sex Transm Dis* 1999, **26**:496-499.

19. Westrom L, Eschenbach D: **Pelvic inflammatory disease**. In *Sexually Transmitted Diseases Volume 58*. Third edition. Edited by: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WE, Piot P and Wasserheit JN. New York, McGraw-Hill; 1999:783-809.
20. Gutman LT: **Gonococcal diseases in infants and children**. In *Sexually Transmitted Diseases Volume 82*. Third edition. Edited by: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WE, Piot P and Wasserheit JN. New York, McGraw-Hill; 1999:1145-1153.
21. Marrazzo JM, Celum CL, White C, Handsfield HH: **Cost-effectiveness of urine-based screening for Chlamydia trachomatis with ligase chain reaction in asymptomatic males**. In *Proceedings of the 13th Meeting of the International Society for Sexually Transmitted Disease Research* Denver, CO; 1999.
22. Magid D, Douglas JM Jr., Schwartz JS: **Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis**. *Ann Int Med* 1996, **124**:389-399.
23. Rein DB, Kassler WJ, Irwin KL, Rabiee L: **Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial**. *Obstet Gynecol* 2000, **95**:397-402.
24. Yeh JM, Hook EW III, Goldie SJ: **A refined estimate of the average lifetime cost of pelvic inflammatory disease**. *Sex Transm Dis* 2003, **30**:369-378.
25. Rein DB, Gift TL: **A refined estimate of the lifetime cost of pelvic inflammatory disease**. *Sex Transm Dis* 2004, **31**:325.
26. Gift TL, Owens CJ: **The direct medical cost of epididymitis and orchitis: Evidence from a study of insurance claims**. *Sex Transm Dis* 2006, **33**:S84-S88.
27. Centers for Disease Control and Prevention: **Sexually transmitted diseases treatment guidelines, 2006**. *MMWR Recomm Rep* 2006, **55**:1-94.
28. Wasserheit JN, Valdiserri RO, Wood RW: **Assessment of STD/HIV prevention programs in the United States: national, local, and community perspectives**. In *Sexually Transmitted Diseases Volume 90*. Third edition. Edited by: Holmes KK, Sparling PF, Mardh P, Lemon SE, Stamm WE, Piot P and Wasserheit JN. New York, McGraw-Hill; 1999:1255-1271.
29. Singh AE, Romanowski B: **Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features**. *Clin Microbiol Rev* 1999, **12**:187-209.
30. Landers DV, Wiesenfeld HC, Heine RP, Krohn MA, Hillier SL: **Predictive value of the clinical diagnosis of lower genital tract infection in women**. *Am J Obstet Gynecol* 2004, **190**:1004-1010.
31. Finelli L, Nakashima AK, Hillis S, Crayne E, Spitalny KC: **Selective screening versus presumptive treatment criteria for identification of women with chlamydial infection in public clinics: New Jersey**. *Am J Obstet Gynecol* 1996, **174**:1527-1533.
32. Ryan CA, Courtois BN, Hawes SE, Stevens CE, Eschenbach DA, Holmes KK: **Risk assessment, symptoms, and signs as predictors of vulvovaginal and cervical infections in an urban US STD clinic: implications for use of STD algorithms**. *Sex Transm Infect* 1998, **74 Suppl 1**:S59-S76.
33. DiCarlo RP, Martin DH: **The clinical diagnosis of genital ulcer disease in men**. *Clin Infect Dis* 1997, **25**:292-298.
34. Khan A, Fortenberry JD, Julian BE, Tu W, Orr DP, Batteiger BE: **The prevalence of chlamydia, gonorrhea, and trichomonas in sexual partnerships: implications for partner notification and treatment**. *Sex Transm Dis* 2005, **32**:260-264.
35. Rothenberg RB, Potterat JJ: **Partner notification for sexually transmitted disease and HIV infection**. In *Sexually Transmitted Diseases Volume 55*. Third edition. Edited by: Holmes KK, Sparling PF, Mardh P, Lemon SE, Stamm WE, Piot P and Wasserheit JN. New York, McGraw-Hill; 1999:745-752.
36. Ruden AK, Jonsson A, Lidbrink P, Allebeck P, Bygdeman SM: **Endemic versus non-endemic gonorrhoea in Stockholm: results of contact tracing**. *Int J STD AIDS* 1993, **4**:284-292.
37. Samoff E, Koumans EH, Katkowsky S, Shouse RL, Markowitz LE: **Contact-tracing outcomes among male syphilis patients in Fulton County, Georgia, 2003**. *Sex Transm Dis* 2007, **34**:456-460.
38. Gunn RA, Montes JM, Toomey KE, Rolfs RT, Greenspan JR, Spitters CE, Waterman SH: **Syphilis in San Diego County 1983-1992: crack cocaine, prostitution, and the limitations of partner notification**. *Sex Transm Dis* 1995, **22**:60-66.
39. Engelgau MM, Woernerl CH, Rolfs RT, Greenspan JR, O'Cain M, Gorsky RD: **Control of epidemic early syphilis: the results of an intervention campaign using social networks**. *Sex Transm Dis* 1995, **22**:203-209.
40. Sparling PF: **Natural history of syphilis**. In *Sexually Transmitted Diseases Volume 34*. Third edition. Edited by: Holmes KK, Sparling PF, Mardh P, Lemon SE, Stamm WE, Piot P and Wasserheit JN. New York, McGraw-Hill; 1999:473-478.
41. Schroeter AL, Turner RH, Lucas JB, Brown WJ: **Therapy for incubating syphilis. Effectiveness of gonorrhea treatment**. *JAMA* 1971, **218**:711-713.
42. Lyss SB, Kamb ML, Peterman TA, Moran JS, Newman DR, Bolan G, Douglas JM Jr., Iatesta M, Malotte CK, Zenilman JM, Ehret J, Gaydos C, Newhall WJ: **Chlamydia trachomatis among patients infected with and treated for Neisseria gonorrhoeae in sexually transmitted disease clinics in the United States**. *Ann Intern Med* 2003, **139**:178-185.
43. Creighton S, Tenant-Flowers M, Taylor CB, Miller R, Low N: **Coinfection with gonorrhoea and chlamydia: how much is there and what does it mean?** *Int J STD AIDS* 2003, **14**:109-113.
44. Levitt MA, Johnson S, Engelstad L, Montana R, Stewart S: **Clinical management of chlamydia and gonorrhea infection in a county teaching emergency department--concerns in over-treatment, undertreatment, and follow-up treatment success**. *J Emerg Med* 2003, **25**:7-11.
45. Lifson AR, Halcon LL, Hannan P, St LME, Hayman CR: **Screening for sexually transmitted infections among economically disadvantaged youth in a national job training program**. *J Adolesc Health* 2001, **28**:190-196.
46. Miller WC, Ford CA, Morris M, Handcock MS, Schmitz JL, Hobbs MM, Cohen MS, Harris KM, Udry JR: **Prevalence of chlamydial and gonococcal infections among young adults in the United States**. *JAMA* 2004, **291**:2229-2236.
47. Bachmann LH, Pigott D, Desmond R, Jones M, Lumpkins J, Gala P, Terndrup T, Hook EW III: **Prevalence and factors associated with gonorrhea and chlamydia infection in at-risk females presenting to an urban emergency department**. *Sex Transm Dis* 2003, **30**:335-339.
48. Nsuami M, Cammarata CL, Brooks BN, Taylor SN, Martin DH: **Chlamydia and gonorrhea co-occurrence in a high school population**. *Sex Transm Dis* 2004, **31**:424-427.
49. Dicker LW, Mosure DJ, Berman SM, Levine WC: **Gonorrhea prevalence and coinfection with chlamydia in women in the United States, 2000**. *Sex Transm Dis* 2003, **30**:472-476.
50. Whittington WL, Kent C, Kissinger P, Oh MK, Fortenberry JD, Hillis SE, Litchfield B, Bolan GA, St Louis ME, Farley TA, Handsfield HH: **Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study**. *Sex Transm Dis* 2001, **28**:117-123.
51. Richey CM, Macaluso M, Hook EW: **Determinants of reinfection with Chlamydia trachomatis**. *Sex Transm Dis* 1999, **26**:4-11.
52. Bernstein KT, Zenilman J, Olthoff G, Marsiglia VC, Erbeling EJ: **Gonorrhea reinfection among sexually transmitted disease clinic attendees in Baltimore, Maryland**. *Sex Transm Dis* 2006, **33**:80-86.
53. Schillinger JA, Kissinger P, Calvet H, Whittington WL, Ransom RL, Sternberg MR, Berman SM, Kent CK, Martin DH, Oh MK, Handsfield HH, Bolan G, Markowitz LE, Fortenberry JD: **Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial**. *Sex Transm Dis* 2003, **30**:49-56.
54. Golden MR, Whittington WL, Handsfield HH, Hughes JP, Stamm WE, Hogben M, Clark A, Malinski C, Helters JR, Thomas KK, Holmes KK: **Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection**. *N Engl J Med* 2005, **352**:676-685.
55. Chamot E, Coughlin SS, Farley TA, Rice JC: **Gonorrhea incidence and HIV testing and counseling among adolescents and young adults seen at a clinic for sexually transmitted diseases**. *AIDS* 1999, **13**:971-979.
56. Ellen JM, Hessol NA, Kohn RP, Bolan GA: **An investigation of geographic clustering of repeat cases of gonorrhea and chlamydial infection in San Francisco, 1989-1993: evidence for core groups**. *J Infect Dis* 1997, **175**:1519-1522.
57. Fortenberry JD, Brizendine EJ, Katz BP, Wools KK, Blythe MJ, Orr DP: **Subsequent sexually transmitted infections among adolescent women with genital infection due to Chlamydia tra-**

- chomatis, *Neisseria gonorrhoeae*, or *Trichomonas vaginalis*. *Sex Transm Dis* 1999, **26**:26-32.
58. Gunn RA, Maroufi A, Fox KK, Berman SM: **Surveillance for repeat gonorrhea infection, San Diego, California, 1995-2001: establishing definitions and methods.** *Sex Transm Dis* 2004, **31**:373-379.
 59. Gunn RA, Fitzgerald S, Aral SO: **Sexually transmitted disease clinic clients at risk for subsequent gonorrhea and chlamydia infections: possible 'core' transmitters.** *Sex Transm Dis* 2000, **27**:343-349.
 60. Oh MK, Cloud GA, Fleenor M, Sturdevant MS, Nesmith JD, Feinstein RA: **Risk for gonococcal and chlamydial cervicitis in adolescent females: incidence and recurrence in a prospective cohort study.** *J Adolesc Health* 1996, **18**:270-275.
 61. Orr DP, Johnston K, Brizendine E, Katz B, Fortenberry JD: **Subsequent sexually transmitted infection in urban adolescents and young adults.** *Arch Pediatr Adolesc Med* 2001, **155**:947-953.
 62. Thomas JC, Weiner DH, Schoenbach VJ, Earp JA: **Frequent re-infection in a community with hyperendemic gonorrhoea and chlamydia: appropriate clinical actions.** *Int J STD AIDS* 2000, **11**:461-467.
 63. Radolf JD, Sanchez PJ, Schulz KF, Murphy FK: **Congenital syphilis.** In *Sexually Transmitted Diseases Volume 84*. Third edition. Edited by: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WE, Piot P and Wasserheit JN. New York, McGraw-Hill; 1999:1165-1189.
 64. de Lissovoy G, Zenilman J, Nelson KE, Ahmed F, Celentano DD: **The cost of a preventable disease: estimated U.S. national medical expenditures for congenital syphilis, 1990.** *Public Health Rep* 1995, **110**:403-409.
 65. Bateman DA, Phipps CS, Joyce T, Heagarty MC: **The hospital cost of congenital syphilis.** *J Pediatr* 1997, **130**:752-758.
 66. Welte R, Postma M, Leidl R, Kretzschmar M: **Costs and effects of chlamydial screening: dynamic versus static modeling.** *Sex Transm Dis* 2005, **32**:474-483.
 67. Pinkerton SD, Holtgrave DR, Johnson-Masotti AP, Turk ME, Hackl KL, DiFranceisco W, NIMH Multisite HIV Prevention Trial Group: **Cost-effectiveness of the NIMH multisite HIV prevention intervention.** *AIDS Behav* 2002, **6**:83-96.
 68. Wasserheit JN: **Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases.** *Sex Transm Dis* 1992, **19**:61-77.
 69. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, Mayaud P, Chagalucha J, Nicoll A, Kagina G, Newell J, Mugeye K, Mabey D, Hayes R: **Impact of Improved Treatment of Sexually-Transmitted Diseases on HIV-Infection in Rural Tanzania - Randomized Controlled Trial.** *Lancet* 1995, **346**:530-536.
 70. Chesson HW, Pinkerton SD: **Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions.** *J Acquir Immune Defic Syndr* 2000, **24**:48-56.
 71. Kerani RP, Handsfield HH, Stenger MS, Shafii T, Zick E, Brewer D, Golden MR: **Rising rates of syphilis in the era of syphilis elimination.** *Sex Transm Dis* 2007, **34**:154-161.
 72. Buchacz K, Greenberg A, Onorato I, Janssen R: **Syphilis epidemics and human immunodeficiency virus (HIV) incidence among men who have sex with men in the United States: implications for HIV prevention.** *Sex Transm Dis* 2005, **32**:S73-S79.
 73. Hogben M, Paffel J, Broussard D, Wolf W, Kenney K, Rubin S, George D, Samoff E: **Syphilis partner notification with men who have sex with men: a review and commentary.** *Sex Transm Dis* 2005, **32**:S43-S47.
 74. Paz-Bailey G, Meyers A, Blank S, Brown J, Rubin S, Braxton J, Zaidi A, Schafzin J, Weigl S, Markowitz LE: **A case-control study of syphilis among men who have sex with men in New York City: association with HIV infection.** *Sex Transm Dis* 2004, **31**:581-587.
 75. Taylor M, Aynalem G, Smith L, Bemis C, Kenney K, Kerndt P: **Correlates of Internet use to meet sex partners among men who have sex with men diagnosed with early syphilis in Los Angeles County.** *Sex Transm Dis* 2004, **31**:552-556.
 76. Pinkerton SD, Chesson HW, Holtgrave DR, Kassler W, Layde PM: **When is an HIV infection prevented and when is it merely delayed?** *Eval Rev* 2000, **24**:251-271.
 77. Truong HHM, Kellogg T, Klausner JD, Katz MH, Dilley J, Knapper K, Chen S, Prabhu R, Grant RM, Louie B, McFarland W: **Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting?** *Sex Transm Infect* 2006, **82**:461-466.
 78. Varghese B, Peterman TA, Holtgrave DR: **Cost-effectiveness of counseling and testing and partner notification: a decision analysis.** *AIDS* 1999, **13**:1745-1751.
 79. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR III, Losina E, Zhang H, Freedberg KA, Walensky RP: **Expanded screening for HIV in the United States--an analysis of cost-effectiveness.** *N Engl J Med* 2005, **352**:586-595.
 80. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK: **Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.** *N Engl J Med* 2005, **352**:570-585.
 81. Cohen DA, Wu SY, Farley TA: **Comparing the cost-effectiveness of HIV prevention interventions.** *J Acquir Immune Defic Syndr* 2004, **37**:1404-1414.
 82. MacKellar DA, Valleroy LA, Secura GM, Bartholow BN, McFarland W, Shehan D, Ford W, LaLota M, Celentano DD, Koblin BA, Torian LV, Perdue TE, Janssen RS: **Repeat HIV testing, risk behaviors, and HIV seroconversion among young men who have sex with men: a call to monitor and improve the practice of prevention.** *J Acquir Immune Defic Syndr* 2002, **29**:76-85.
 83. Centers for Disease Control and Prevention: **HIV counseling and testing in publicly funded sites: Annual report 1997 and 1998.** Atlanta GA, Centers for Disease Control and Prevention; 2001.
 84. Priddy FH, Pilcher CD, Moore RH, Tampe P, Park MN, Fiscus SA, Feinberg MB, del RC: **Detection of acute HIV infections in an urban HIV counseling and testing population in the United States.** *J Acquir Immune Defic Syndr* 2007, **44**:196-202.
 85. Blandford JM, Gift TL: **Productivity losses attributable to untreated chlamydial infection and associated pelvic inflammatory disease in reproductive-aged women.** *Sex Transm Dis* 2006, **33**:S117-S121.
 86. Institute of Medicine (Committee on Prevention and Control of Sexually Transmitted Diseases): *The Hidden Epidemic: Confronting Sexually Transmitted Diseases* Edited by: Eng TR and Butler WT. Washington, D.C. National Academy Press; 1997.
 87. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ: **Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach.** *Medical Decision Making* 1985, **5**:157-177.
 88. Heffelfinger JD, Swint EB, Berman SM, Weinstock HS: **Trends in primary and secondary syphilis among men who have sex with men in the United States.** *Am J Public Health* 2007, **97**:1076-1083.
 89. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S: **Births: final data for 2004.** *Natl Vital Stat Rep* 2006, **55**:1-101.
 90. Low N, Egger M, Sterne JA, Harbord RM, Ibrahim F, Lindblom B, Herrmann B: **Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women's Cohort Study.** *Sex Transm Infect* 2006, **82**:212-218.
 91. Garnett GP: **An introduction to mathematical models in sexually transmitted disease epidemiology.** *Sex Transm Infect* 2002, **78**:7-12.
 92. Centers for Disease Control and Prevention: *Sexually Transmitted Disease Surveillance, 2005* Atlanta, U.S. Department of Health and Human Services; 2006.
 93. Blocker ME, Levine WC, St Louis ME: **HIV prevalence in patients with syphilis, United States.** *Sex Transm Dis* 2000, **27**:53-59.
 94. Stray-Pedersen B: **Economic evaluation of maternal screening to prevent congenital syphilis.** *Sex Transm Dis* 1983, **10**:167-172.
 95. Silberstein GS, Coles FB, Greenberg A, Singer L, Voigt R: **Effectiveness and cost-benefit of enhancements to a syphilis screening and treatment program at a county jail.** *Sex Transm Dis* 2000, **27**:508-517.